Article
Validation of a rapid HLA-DQA1*05 pharmacogenomics assay to identify at-risk resistance to anti-tumor necrosis factor therapy among patients with inflammatory bowel disease.
American journal of clinical pathology - 1 Aug 2023
DelBaugh Regina M, Cook Leanne J, Siegel Corey A, Tsongalis Gregory J, Khan Wahab A
Abstract excerpt
OBJECTIVES: The HLA-DQA1*05 variant (rs2097432) is associated with increased risk of immunogenicity to tumor necrosis factor antagonists, with subsequent resistance to therapy in patients with inflammatory bowel disease. Identification of these patients would optimize personalized therapeutic selection. METHODS: Genomic DNA was extracted from 80 deidentified samples in an unselected patient population with an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.